Precision medicine in Alzheimer's disease aims to personalize treatment based on an individual's genetic, biomarker, and lifestyle data. This approach acknowledges the heterogeneity of Alzheimer's, where symptoms and progression vary widely among patients. By analyzing genetic markers like APOE ε4 allele and biomarkers such as amyloid and tau proteins, clinicians can better predict disease risk, tailor interventions, and monitor treatment responses more effectively. Precision medicine also explores targeted therapies that address specific molecular pathways implicated in Alzheimer's pathology, potentially slowing or modifying disease progression. Integrating advanced technologies like genomics and neuroimaging enhances early detection and intervention strategies, offering hope for more personalized and effective care for individuals affected by Alzheimer's and related dementias.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China